Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) major shareholder Invest Corp Pillar sold 2,300,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $1.96, for a total value of $4,508,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Invest Corp Pillar also recently made the following trade(s):

  • On Wednesday, December 13th, Invest Corp Pillar sold 1,100,000 shares of Idera Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total value of $2,123,000.00.

Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) traded down $0.08 during midday trading on Friday, hitting $1.87. The stock had a trading volume of 5,616,139 shares, compared to its average volume of 1,515,704. Idera Pharmaceuticals, Inc. has a 1-year low of $1.30 and a 1-year high of $2.87.

Idera Pharmaceuticals (NASDAQ:IDRA) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.20 million. Idera Pharmaceuticals had a negative return on equity of 60.80% and a negative net margin of 313.78%. research analysts forecast that Idera Pharmaceuticals, Inc. will post -0.42 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in shares of Idera Pharmaceuticals by 45.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,359,875 shares of the biotechnology company’s stock valued at $7,526,000 after purchasing an additional 1,048,475 shares during the last quarter. State Street Corp grew its stake in shares of Idera Pharmaceuticals by 13.0% in the 2nd quarter. State Street Corp now owns 1,787,852 shares of the biotechnology company’s stock valued at $3,075,000 after purchasing an additional 205,217 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Idera Pharmaceuticals by 3.5% in the 2nd quarter. Vanguard Group Inc. now owns 5,181,108 shares of the biotechnology company’s stock valued at $8,911,000 after purchasing an additional 173,775 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Idera Pharmaceuticals by 846.1% in the 2nd quarter. GSA Capital Partners LLP now owns 180,588 shares of the biotechnology company’s stock valued at $311,000 after purchasing an additional 161,500 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Idera Pharmaceuticals by 93.9% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 322,929 shares of the biotechnology company’s stock valued at $798,000 after purchasing an additional 156,400 shares during the last quarter. 24.18% of the stock is currently owned by institutional investors.

IDRA has been the topic of a number of analyst reports. HC Wainwright initiated coverage on Idera Pharmaceuticals in a research report on Thursday, November 9th. They issued a “buy” rating and a $4.00 price target on the stock. Piper Jaffray Companies reissued a “buy” rating and set a $4.00 target price on shares of Idera Pharmaceuticals in a research report on Tuesday, September 12th. Zacks Investment Research raised Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, BidaskClub lowered Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $4.83.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Idera Pharmaceuticals, Inc. (IDRA) Major Shareholder Sells 2,300,000 Shares of Stock” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/15/insider-selling-idera-pharmaceuticals-inc-idra-major-shareholder-sells-2300000-shares-of-stock.html.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.